16 December 2015 - In final guidance as part of its Highly Specialised Technologies Programme, NICE has recommended Elosulfase alfa (Vimizin, BioMarin) for the treatment of mucopolysaccharidosis type IVa (also known as MPS IVa and Morquio A syndrome).

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-recommends-elosulfase-alfa-vimizim-for-treatment-of-very-rare-life-limiting-genetic-disorder-under-managed-access-agreement